Risk stratification strategies for cancer-associated thrombosis: An update

Thrombosis Research

Volumn 133, Issue SUPPL. 2, 2014, Pages

  Khorana, Alok A ^a   McCrae, Keith R ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Cancer; Prevention; Risk factors; Venous thromboembolism

Indexed keywords

THROMBOPLASTIN; TUMOR MARKER;

ARTICLE; CANCER ASSOCIATED THROMBOSIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER THERAPY; DISEASE ASSOCIATION; LEUKOCYTE COUNT; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SYSTEMIC THERAPY; THROMBOCYTE COUNT; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; HUMAN; NEOPLASMS; ONCOLOGY; STANDARDS;

HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84901428841     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(14)50006-0     Document Type: Article

References (37)

1. A.A. Khorana, M. Dalal, J. Lin, and G.C. Connolly Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States Cancer 119 2013 648 655
2. R.A. Moore, N. Adel, E. Riedel, M. Bhutani, D.R. Feldman, and N.E. Tabbara et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis J Clin Oncol 29 2011 3466 3473
3. F. Horsted, J. West, and M.J. Grainge Risk of venous thromboembolism in patients with cancer: A systematic review and meta-analysis PLoS Medicine 9 2012 e1001275
4. G.H. Lyman, A.A. Khorana, N.M. Kuderer, A.Y. Lee, J.I. Arcelus, and E.P. Balaban et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 31 2013 2189 2204
5. A.A. Khorana, and G.C. Connolly Assessing risk of venous thromboembolism in the patient with cancer J Clin Oncol 27 2009 4839 4847
6. J.W. Blom, C.J. Doggen, S. Osanto, and F.R. Rosendaal Malignancies, prothrombotic mutations, and the risk of venous thrombosis JAMA 293 2005 715 722 (Pubitemid 40216041)
7. B. Dickmann, J. Ahlbrecht, C. Ay, D. Dunkler, J. Thaler, and W. Scheithauer et al. Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study Haematologica 98 2013 1309 1314
8. F.A. Scappaticci, L. Fehrenbacher, T. Cartwright, J.D. Hainsworth, W. Heim, and J. Berlin et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab J Surg Oncol 91 2005 173 180 (Pubitemid 41254420)
9. T.K. Choueiri, F.A. Schutz, Y. Je, J.E. Rosenberg, and J. Bellmunt Risk of arterial thromboembolic events with sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials J Clin Oncol 28 2010 2280 2285
10. M. Cavo, E. Zamagni, C. Cellini, P. Tosi, D. Cangini, and M. Cini et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy Blood 100 2002 2272 2273 (Pubitemid 35001274)
11. F. Petrelli, M. Cabiddu, K. Borgonovo, and S. Barni Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: A meta-analysis of randomized clinical trials Ann Oncol 23 2012 1672 1679
12. G. Agnelli, G. Gussoni, C. Bianchini, M. Verso, M. Mandala, and L. Cavanna et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study Lancet Oncol 10 2009 943 949
13. G. Agnelli, D.J. George, A.K. Kakkar, W. Fisher, M.R. Lassen, and P. Mismetti et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer N Engl J Med 366 2012 601 609
14. A. Palumbo, S.V. Rajkumar, M.A. Dimopoulos, P.G. Richardson, J. San Miguel, and B. Barlogie et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma Leukemia 22 2008 414 423 (Pubitemid 351255436)
15. A. Maraveyas, J. Waters, R. Roy, D. Fyfe, D. Propper, and F. Lofts et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer Eur J Cancer 48 2012 1283 1292
16. I. Pabinger, J. Thaler, and C. Ay Biomarkers for prediction of venous thromboembolism in cancer Blood 122 2013 2011 2018
17. J.I. Zwicker, H.A. Liebman, K.A. Bauer, T. Caughey, F. Campigotto, and R. Rosovsky et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: A randomized-controlled phase II trial (the Microtec study) Br J Haematol 160 2012 530 537
18. A. Bharthuar, A.A. Khorana, A. Hutson, J.G. Wang, N.S. Key, and N. Mackman et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers Thromb Res 132 2013 180 184
19. J. Thaler, C. Ay, N. Mackman, R.M. Bertina, A. Kaider, and C. Marosi et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients J Thromb Haemost 10 2012 1363 1370
20. A.A. Khorana, N.M. Kuderer, E. Culakova, G.H. Lyman, and C.W. Francis Development and validation of a predictive model for chemotherapy-associated thrombosis Blood 111 2008 4902 4907
21. C. Ay, D. Dunkler, C. Marosi, A.L. Chiriac, R. Vormittag, and R. Simanek et al. Prediction of venous thromboembolism in cancer patients Blood 116 2010 5377 5382
22. M. Mandala, M. Clerici, I. Corradino, C. Vitalini, S. Colombini, and V. Torri et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience' Ann Oncol 23 2012 1416 1421
23. A.A. Khorana Cancer and coagulation Am J Hematol 87 Suppl 1 2012 S82 S87
24. T.G. McGinn, G.H. Guyatt, P.C. Wyer, C.D. Naylor, I.G. Stiell, and W.S. Richardson Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group JAMA 284 2000 79 84 (Pubitemid 30445665)
25. M.B. Streiff et al. NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease 2013 http://www.nccn.org/professionals/physician-gls/pdf/ vte.pdf
26. M. Mandala, A. Falanga, and F. Roila Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines Ann Oncol 22 Suppl 6 2011 vi85 vi92
27. M. Verso, G. Agnelli, S. Barni, G. Gasparini, and R. LaBianca A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score Intern Emerg Med 7 2012 291 292
28. T. Sousou, and A.A. Khorana Cancer patients and awareness of venous thromboembolism Cancer Invest 28 2010 44 45
29. S. Le Sage, M. McGee, and J.D. Emed Knowledge of venous thromboembolism (VTE) prevention among hospitalized patients J Vasc Nurs 26 2008 109 117
30. D.B. Lustig, P. Wells, R. Rodriguez, and I. Dao Implementing a Computerized Care Process Management System To Determine The Feasibility Of Utilizing, and Concomitantly Validating, a Prediction Tool For The Risk Of Venous Thromboembolism In Cancer Patients. American Society of Hematology Blood 2013 New Orleans, LA, p. Abs 1688
31. A.A. Khorana, K. Herman, D. Rubens, and C.W. Francis A Predictive Risk Score for Cancer-Associated Thrombosis: Role of Screening in A Prospective Study Blood 2010 Abstract 3173
32. M. Verso, G. Agnelli, S. Barni, G. Gasparini, and R. Labianca A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score Intern Emerg Med 7 2012 291 292
33. D.J. George, G. Agnelli, W. Fisher, K. AK, M.R. Lassen, and P. Mismetti et al. Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO Blood ASH Annual Meeting Program and Proceedings 2011
34. A.S. Epstein, and E.M. O'Reilly Exocrine pancreas cancer and thromboembolic events: A systematic literature review J Natl Compr Canc Netw 10 2012 835 846
35. A. Palumbo, M. Cavo, S. Bringhen, E. Zamagni, A. Romano, and F. Patriarca et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial J Clin Oncol 29 2011 986 993
36. J.R. Perry, J.A. Julian, N.J. Laperriere, W. Geerts, G. Agnelli, and L.R. Rogers et al. PRODIGE: A randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma J Thromb Haemost 8 2010 1959 1965
37. A.A. Khorana Venous thromboembolism prevention in cancer outpatients J Natl Compr Canc Netw 11 2013 1431 1438